The DOI matches its Crossref record.
Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Abstract
PURPOSE: Docetaxel is a highly active antineoplastic agent; however, grade IV leukopenia occurs in the large majority of patients treated with a dose of 100 mg/m2 every 3 weeks. Recent experience with weekly paclitaxel has demonstrated a bone marrow-sparing effect when a weekly administration schedule is used. We investigated a weekly schedule of docetaxel in an attempt to alter the toxicity profile and improve the therapeutic index. PATIENTS AND METHODS: Thirty-eight patients with advanced, refractory malignancy entered this phase I trial between October 1996 and June 1997. Docetaxel was administered weekly for 6 consecutive weeks, followed by 2 weeks without treatment. Sequential cohorts of patients were treated at the following dose levels: 20, 25, 30, 36, 43, and 52 mg/m2. Patients were reevaluated after one course (8 weeks); patients with objective response or stable disease continued treatment for a maximum of four courses or until disease progression. RESULTS: Thirty-five patients completed at least one course of therapy. Myelosuppression was not a dose-limiting toxicity (DLT) at any of the doses tested. Only five episodes of grade III leukopenia occurred (14% of patients, 2% of doses), and no grade IV leukopenia was produced. No grade III or IV thrombocytopenia or anemia was observed. Grade III fatigue and asthenia were observed in all three patients treated at 52 mg/m2/wk and in two of 10 at 43 mg/m2/wk. Other grade III toxicity included acral erythema (n = 1), neuropathy (n = 1), peripheral edema (n = 1), and diarrhea (n = 1). The DLTs of this docetaxel schedule are fatigue and asthenia. Although the maximum-tolerated dose by definition of this study was 43 mg/m2/wk, we selected 36 mg/m2/wk for ongoing phase II studies. CONCLUSION: The toxicity profile of docetaxel is markedly altered when the drug is administered by a weekly schedule. Myelosuppression is mild and uncommon. Fatigue and asthenia are the DLTs; other nonhematologic toxicities, which included peripheral edema and neuropathy, are uncommon, and the arthralgia/myalgia syndrome was not observed. Weekly administration of docetaxel may provide a better tolerated, efficacious use of this drug; further investigation of weekly docetaxel as a single agent and in combination regimens is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Curcumin and cancer: An “old-age” disease with an “age-old” solution
Anand, P., Sundaram, C., Jhurani, S., Kunnumakkara, A. B., & Aggarwal, B. B. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.025 · Cited by 1,132
Clinical Pharmacokinetics of Docetaxel
Clarke, S. J., & Rivory, L. P. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936020-00002 · Cited by 446
Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer
Burstein, H. J., Manola, J., Younger, J., Parker, L. M., Bunnell, C. A., Scheib, R., Matulonis, U. A., Garber, J. E., Clarke, K. D., Shulman, L. N., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1212 · Cited by 260
Monk, J. P., Phillips, G., Waite, R., Kuhn, J., Schaaf, L. J., Otterson, G. A., Guttridge, D., Rhoades, C., Shah, M., Criswell, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2838 · Cited by 179
Metadata
- Authors
- Hainsworth, J. D., Burris, H. A., Erland, J. B., Thomas, M., & Greco, F. A.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-06
- Volume
- 16
- Issue
- 6
- Pages
- 2164-2168
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1920828316
- Cited by
- 249
- References
- 0
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. https://app.cochat.ai/papers/10.1200/jco.1998.16.6.2164
- The paper
- Hainsworth, J. D., Burris, H. A., Erland, J. B., Thomas, M., & Greco, F. A. (1998). Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1998.16.6.2164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.